Compare MGIH & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | QNRX |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 14.5M |
| IPO Year | 2022 | 2023 |
| Metric | MGIH | QNRX |
|---|---|---|
| Price | $1.44 | $7.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 88.1K |
| Earning Date | 10-28-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.21 |
| 52 Week High | $4.84 | $41.80 |
| Indicator | MGIH | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 41.42 |
| Support Level | $1.41 | $6.85 |
| Resistance Level | $1.53 | $7.80 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 13.04 | 5.11 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.